Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis

Primary Liver Cancer (PLC) is the leading cause of death by cancer among males in Thailand and the 3rd among females. Most cases are hepatocellular carcinoma (HCC) but cholangiocarcinomas represent between 4 and 80% of liver cancers depending upon geographic area. Most HCC are associated with chronic infection by Hepatitis B Virus while a G→T mutation at codon 249 of the TP53 gene, R249S, specific for exposure to aflatoxin, is detected in tumors for up to 30% of cases. We have used Short Oligonucleotide Mass Analysis (SOMA) to quantify free circulating R249S-mutated DNA in plasma using blood specimens collected in a hospital case:control study. Plasma R249S-mutated DNA was detectable at low concentrations (≥67 copies/mL) in 53 to 64% of patients with primary liver cancer or chronic liver disease and in 19% of controls. 44% of patients with HCC and no evidence of cirrhosis had plasma concentrations of R249S-mutated DNA ≥150 copies/mL, compared to 21% in patients with both HCC and cirrhosis, 22% in patients with cholangiocarcinoma, 12% in patients with non-cancer chronic liver disease and 3% of subjects in the reference group. Thus, plasma concentrations of R249S-mutated DNA ≥150 copies/mL tended to be more common in patients with HCC developing without pre-existing cirrhosis (p = 0.027). Overall, these results support the preferential occurrence of R249S-mutated DNA in HCC developing in the absence of cirrhosis in a context of HBV chronic infection.

[1]  H. Whittle,et al.  Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection , 2011, Environmental health perspectives.

[2]  P. Hainaut,et al.  Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand , 2011, Hepatitis research and treatment.

[3]  G. Leroux-Roels,et al.  Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region , 2011, Journal of viral hepatitis.

[4]  H. Whittle,et al.  Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[5]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[6]  Hai-rim Shin,et al.  Epidemiology of cholangiocarcinoma: An update focusing on risk factors , 2010, Cancer science.

[7]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[8]  P. Hainaut,et al.  The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. , 2009, Cancer letters.

[9]  P. Hainaut,et al.  In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. , 2009, Gastroenterology.

[10]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[11]  P. Vineis,et al.  Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.

[12]  Douglas L. Park,et al.  Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries , 2006, Environmental health perspectives.

[13]  J. Goedert,et al.  Quantitative Analysis of Plasma TP53 249Ser-Mutated DNA by Electrospray Ionization Mass Spectrometry , 2005, Cancer Epidemiology Biomarkers & Prevention.

[14]  N. Maneekarn,et al.  Hepatitis B 1762T/1764A Mutations, Hepatitis C Infection, and Codon 249 p53 Mutations in Hepatocellular Carcinomas from Thailand , 2005, Cancer Epidemiology Biomarkers & Prevention.

[15]  H. Sriplung,et al.  Epidemiology of liver cancer: an overview. , 2004, Asian Pacific journal of cancer prevention : APJCP.

[16]  T. Yoshizawa,et al.  In-house direct cELISA for determining aflatoxin B 1 in Thai corn and peanuts , 2003, Food additives and contaminants.

[17]  B. Stewart,et al.  World Cancer Report , 2003 .

[18]  Leslie T. Stayner,et al.  IARC Monographs on the evaluation of carcinogenic risks to humans: Some traditional herbal medicines, some mycotoxins, naphthalene and styrene , 2002 .

[19]  M. Feitelson,et al.  Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.

[20]  S. Chunsuttiwat,et al.  Impact of hepatitis B immunisation as part of the EPI. , 2000, Vaccine.

[21]  G. Meijer GLOBOCAN 1: Cancer Incidence and Mortality Worldwide. , 2000 .

[22]  C. Wild,et al.  Liver cancer in Thailand. II. A case‐control study of hepatocellular carcinoma , 1991, International journal of cancer.

[23]  C. Wild,et al.  Mycotoxins and Human Disease: a Largely Ignored Global Health Issue , 2022 .

[24]  J. Groopman,et al.  Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. , 2005, Cancer biomarkers : section A of Disease markers.

[25]  Iarc Monographs,et al.  Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. , 2002, IARC monographs on the evaluation of carcinogenic risks to humans.

[26]  J. Goedert,et al.  Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. , 2000, Journal of the National Cancer Institute.

[27]  E. Somers International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.